{"id":60782,"date":"2025-02-13T19:07:51","date_gmt":"2025-02-13T18:07:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/"},"modified":"2025-02-13T19:07:51","modified_gmt":"2025-02-13T18:07:51","slug":"devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/","title":{"rendered":"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)"},"content":{"rendered":"
\n

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian<\/b>\u201d or the \u201cCompany<\/b>\u201d) (TSXV: GSD; OTCQB: DVHGF<\/b>), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new provisional patent application directed to the use of Thykamine\u2122 for treating metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH.<\/p>\n

<\/a>
<\/a><\/p>\n

\nBacked by in vivo<\/i> data, the provisional patent application displays the potential effectiveness of thylakoid extracts in treating and slowing the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH.<\/p>\n

\n\u201cThe filing of this new provisional patent application is another pivotal component of our broad strategy of expanding our already list of patents. Importantly, this filing is timely as we look to demonstrate the potential broad application of our technology,\u201d said Dr. Andr\u00e9 P. Boulet, Chief Scientific Officer of the Company.<\/p>\n

\nAbout MASLD\/MASH1,2<\/sup><\/b><\/p>\n

\nMetabolic dysfunction-associated steatotic liver disease (MASLD) (formerly metabolic (dysfunction) associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD)) is the most common form of chronic liver disease with a worldwide prevalence of 20-30%. It is represented by fat accumulation in the liver, a condition that is commonly associated with features of the metabolic syndrome (MetS), such as obesity, type 2 diabetes, dyslipidemia, and hypertension.<\/p>\n

\nMASLD progresses to metabolic dysfunction-associated steatohepatitis (MASH), the hallmarks of which are inflammation, hepatocellular ballooning, and subsequent worsening fibrosis. Left untreated, MASH can ultimately progress to cirrhosis of the liver and hepatocellular carcinoma, liver failure and death.<\/p>\n

\nAbout Thykamine\u2122<\/b><\/p>\n

\nThykamine\u2122, the first pharmaceutical product issued from Devonian\u2019s SUPREX\u2122 platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine\u2122 have been demonstrated by a considerable number of in vitro<\/i> and in vivo<\/i> studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine\u2122 and SUPREX\u2122 platform are covered by patents issued in several North American, European and Asian countries.<\/p>\n

\nAbout Devonian<\/b><\/p>\n

\nDevonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian\u2019s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian\u2019s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.<\/p>\n

\nDevonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.<\/p>\n

\nDevonian Health Group Inc. was incorporated in 2015 and is headquartered in Qu\u00e9bec, Canada where it owns a state-of-the art extraction facility with full traceability \u2018from the seed to the pill\u2019. Devonian is traded publicly on the TSX Venture Exchange (the \u201cExchange<\/b>\u201d) (TSXV: GSD<\/b>) and on OTCQB<\/b> exchange (OTCQB: DVHGF<\/b>).<\/p>\n

\nFor more information, visit www.groupedevonian.com<\/a><\/p>\n

\nReferences<\/b><\/p>\n

    \n
  1. \nEkstedt M, Nasr P and Kechagias S. Natural History of NAFLD\/NASH. Curr Hepatology Rep. 16:391-397, 2017.<\/li>\n
  2. \nPierantonelli I. and Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: basic Pathogerenic Mechanisms in the Progression from NAFLD to NASH. Transplantation, 103(1): p e1-e13, 2019<\/li>\n<\/ol>\n

    \nCautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n

    \nAll statements, other than statements of historical fact, contained in this press release including but, not limited to those relating to the economical impact of clinical study, the efficiency of the high anti-inflammatory potency proven and the position of the Thykamine\u2122 as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease, the reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences, the grant of the patent and, generally, the above \u201cAbout Devonian\u201d and \u201cAbout Altius\u201d paragraphs, which essentially describes the Corporation\u2019s outlook, constitute \u201cforward-looking information\u201d or \u201cforward-looking statements\u201d within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.<\/p>\n

    \nForward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.<\/p>\n

    \nBy their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management\u2019s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.<\/p>\n

    \nNeither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n

    Contacts<\/b> <\/p>\n

    \nDevonian Health Group Inc.<\/b>
    Mr. Luc Gregoire
    \n
    President & CEO
    \n
    Dr. Andre P. Boulet, PhD
    \n
    Chairman, Chief Scientific Officer
    \n
    Telephone: 1 (450) 979-2916
    \n
    E-mail:     investors@groupedevonian.com<\/a><\/p>\n

    \nRenmark Financial Communications Inc.<\/strong>
    Mr. Ben Ozerkevich
    \n
    Telephone: (416) 644-2020 or (212) 812-7680
    \n
    E-mail:     bozerkevich@renmarkfinancial.com<\/a>
    www.renmarkfinancial.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCompany\u201d) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new provisional patent application directed to the use of Thykamine\u2122 for treating metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH. Backed by in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60782","6":"format-standard","7":"category-industry"},"yoast_head":"\nDevonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCompany\u201d) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new provisional patent application directed to the use of Thykamine\u2122 for treating metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH. Backed by in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-13T18:07:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250213668519\/en\/681971\/22\/logodevonian2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)\",\"datePublished\":\"2025-02-13T18:07:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/\"},\"wordCount\":1122,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250213668519\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/\",\"name\":\"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250213668519\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\",\"datePublished\":\"2025-02-13T18:07:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250213668519\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250213668519\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/","og_locale":"en_US","og_type":"article","og_title":"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Pharma Trend","og_description":"QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCompany\u201d) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new provisional patent application directed to the use of Thykamine\u2122 for treating metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH. Backed by in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/","og_site_name":"Pharma Trend","article_published_time":"2025-02-13T18:07:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250213668519\/en\/681971\/22\/logodevonian2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)","datePublished":"2025-02-13T18:07:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/"},"wordCount":1122,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250213668519\/en\/681971\/22\/logodevonian2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/","url":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/","name":"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250213668519\/en\/681971\/22\/logodevonian2.jpg","datePublished":"2025-02-13T18:07:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250213668519\/en\/681971\/22\/logodevonian2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250213668519\/en\/681971\/22\/logodevonian2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-filing-of-a-new-provisional-patent-application-relating-to-the-use-of-thykamine-for-treating-metabolic-dysfunction-associated-steatohepatitis-mash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine\u2122 for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60782"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60782\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}